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Graphic abstract. Proposed mechanisms of uptake of edelfosine (ET) and lipid 
nanoparticles containing ET (ET-LN) in HL-60 and K-562 leukemia cells  
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ABSTRACT 
The anti-tumor ether lipid edelfosine is the prototype of a novel generation of promising 
anticancer drugs that has been shown to be an effective anti-tumor agent in numerous 
malignancies. However, several cancer types display resistance to different anti-tumor 
compounds due to multi-drug resistance (MDR), which is a major drawback in anticancer 
therapy.  
The leukemic cell line K-562 shows resistance to edelfosine, which can be overcome by the 
use of nanotechnology. The present paper describes the rate and mechanism of 
internalization of free and nano-encapsulated edelfosine. The molecular mechanisms 
underlying this cell death is described in the present paper by characterization of several 
molecules implied in the apoptotic and autophagic pathways (PARP, LC3IIB, Caspases-3, -
9 and -7) and the pattern of expression is compared with cell induction in a sensitive cell 
line HL-60.  
The results showed different internalization patterns in both cells. Clathrin and lipid raft- 
mediated endocytosis were observable in edelfosine uptake whereas these mechanism were 
not visible in the uptake of lipid nanoparticles which might suffer phagocytosis and 
macropinocytosis. Both treatments endorsed caspase-mediated apoptosis in HL-60 cells but 
this cell death was not observed in K-562 cells. Moreover, an important increase in 
autophagic vesicles was visible in K-562 cells. Thus, this mechanism might be implicated 
in the overcoming of K-562 resistance to the treatment by lipid nanoparticles.  
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INTRODUCTION 
The native characteristics of each tumor enable it to be sensitive or refractory to anti-tumor 
agents, and these are the main cause of treatment failure in several cancer types 1-5. In the 
case of chronic myeloid leukemia (CML), the introduction of Imatinib mesylate has 
transformed the preferred treatment. However, patients rarely achieve complete recovery 
due to inherent imatinib-resistant leukemic cells, with characteristics of immature 
progenitors6. 
Therapeutic systems based on the nanometric scale, or nanomedicines, are currently at the 
cutting edge. Among all nanomedicines, lipid nanoparticles (LN) have been shown to be 
effective vehicles for overcoming multi-drug resistance (MDR) in cancer cells 7. Edelfosine 
(ET) is an anti-tumor drug of the family of alkylphospholipids (ALPs) with proven anti-
tumor efficacy 8, 9. Previous studies developed by our research group have shown that LN 
containing ET (ET-LN) are as effective as the free drug and prevent severe side-effects of 
ET such as hemolysis and gastrointestinal toxicity 10, 11. Furthermore, ET-LN are able to 
overcome MDR in leukemia 10 and breast cancer cells 12. These results might be explained 
by the different mechanisms of entry of the free and the encapsulated drug into the cell. 
Different mechanisms of drug incorporation could influence the intracellular concentration 
of ET or might change its intracellular trafficking, and eventually promote cell death. 
Despite the growing interest in research in the field of LN, the cellular uptake mechanism 
of these nanosystems has not yet been clarified and it seems to be dependent on the nature 
of the nanoparticles and the cell type 13. Hence, this research focused on the uptake 
mechanisms of ET and ET-LN in HL-60 and K-562 leukemia cells. In addition, the 
molecular mechanisms implicated in cell death upon internalization of both the drug and 
the ET-LN in the cells was examined.  
LN interact with the cell plasmatic membrane and may be delivered to different 
intracellular compartments upon internalization. The uptake mechanism might entail a 
location of the nanoparticles different from that of the free drug. Mammalian cells follow 
different uptake pathways that promote the delivery of the cargos into subcellular 
compartments. Nanoparticles might enter into the cell either by endocytosis or, to a lesser 
extent, by passive transport 14, 15. Endocytic pathways are typically classified into two 
subtypes: phagocytosis and pinocytosis. Phagocytosis is characteristic of specialized cells 
(with Fc receptors and complement receptors) such as macrophages, monocytes, 
neutrophils and dendritic cells, whereas pinocytosis occurs in all kind of mammalian cells.  
ET uptake by cancer cells has been shown to be dependent on the cell type 16. Raft-
mediated endocytosis seems to be the major entry mechanism in leukemia cells, whereas an 
energy-dependent mechanism involving a lipid transporter/translocase (flippase) has been 
found in carcinoma cells 17-19. Flippases are membrane proteins that translocate 
phospholipids from one leaflet of the bilayer to the opposing leaflet in order to assure the 
assembly and maintenance of the lipid bilayer structure of cellular membranes 20. 
Phospholipid flip-flop in plasmatic membrane of eukaryotic cells is highly regulated and 
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Código de campo cambiado
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Código de campo cambiado
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Código de campo cambiado
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
6 
 
energy-dependent. Lipid translocation from the outer to inner membrane leaflet promotes 
endocytic vesicle formation and accelerates endocytosis by stabilization of the vesicles with 
coat proteins such as clathrin CDE 20. 
The uptake mechanism of a toxic compound into a cell is thought to influence the pathway 
of cell demise. In general, cell death can be achieved by different intracellular mechanisms 
(apoptosis, necrosis, autophagic cell death). Thus, the diverse cell death mechanisms can be 
distinguished according to the cell’s morphological and molecular features 21, 22. 
Several studies have described apoptosis induction in response to drug-loaded nanoparticles 
in cancer cell lines 10, 12, 23, pointing towards the potential of lipid nanoparticles as 
anticancer agents 7. On the other hand, autophagy and autophagic cell death are reported to 
be induced as a response to different classes of nanoparticles such as quantum dots, gold 
nanoparticles, and iron oxide nanoparticles 24-27. However, the role of LN in autophagic cell 
death induction remains unclear.  
It has been previously demonstrated that ET-LN induces stronger cell death than the free 
drug in several leukemic cell lines, overcoming the resistance of K-562 to ET 10, a cell line 
that presents inherent resistance to several compounds 6, 28, 29. Besides, previous flow 
cytometry studies revealed a cell death induction in response to the ET-LN treatment that 
was caused by apoptosis activation in the sensitive cell line HL-60 but not in K-562 10. 
Hence, in the present study these findings were examined at molecular level in order to 
further characterize cell demise induction in response to ET-LN and its possible relation to 
drug uptake.  
EXPERIMENTAL SECTION 
1.1.Chemicals 
ET was purchased from APOINTECH (Salamanca, Spain). Precirol® ATO 5 was a gift 
from Gattefossé (France). Tween® 80 was purchased from Roig Pharma (Barcelona, 
Spain). Chloroform was from Panreac (Madrid, Spain), formic acid 99% for mass 
spectroscopy was obtained from Fluka (Barcelona, Spain), and methanol was purchased 
from Merck (Barcelona, Spain). Ultra-purified water was used throughout and all solvents 
employed for the chromatographic analysis were of analytical grade; all other chemicals 
were of reagent grade and used without further purification. Amicon Ultra-15 10,000 
MWCO centrifugal filter devices were purchased from Millipore (Cork, Ireland). RPMI 
1640 culture media, Heat-inactivated Fetal Bovine Serum (FBS), Glutamax, MEM Non-
Essential Amino Acids and Penicillin/Streptomycin antibiotics were purchased from Life 
Technologies, (Barcelona, Spain). M-PER Mammalian Protein Extraction Reagent was 
purchased from Thermo Fisher Scientific (Madrid, Spain). Protease inhibitor cocktail was 
from Roche (Madrid, Spain). Genistein was purchased from LC Laboratories 
(Massachusetts, USA). Chlorpromazine, Methyl-β-cyclodextrin, Triton-X-100, DTT and 
Phosphate-buffered saline (PBS; 10 mM phosphate, 0.9% NaCl) were obtained from Sigma 
Aldrich Quimica (Madrid, Spain). The antibodies anti-PARP1 (9542), anti-caspase-3 
(9662), anti-caspase-7 (9492), anti-caspase-9 (9508), and anti-LC3 I/II (4108) were 
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purchased from Cell Signaling (Izasa, Barcelona, Spain), and anti-β-actin antibody was 
from Sigma Aldrich (Madrid, Spain).  
1.2.Preparation and characterization of lipid nanoparticles 
LN were prepared by the hot homogenization method consisting of high shear 
homogenization and ultrasonication 11. ET (30 mg) and Precirol® (300 mg) were melted at 
approximately 5ºC above the melting point of the lipid (60ºC). A 2% Tween® 80 aqueous 
solution (10 mL) previously heated at the same temperature was added and dispersed in the 
molten lipid with the help of a Microson™ ultrasonic cell disruptor (NY, USA) and an 
Ultraturrax® (IKA-Werke, Germany). The emulsion was removed from the heat and placed 
in an ice bath to obtain LN by lipid solidification. Then, the LN suspension was centrifuged 
and washed twice with distilled water. Afterwards, 150 % (w/w of lipid weight) trehalose 
was added as cryoprotectant agent to the LN suspension, which was then kept at -80ºC and 
freeze-dried to obtain a nanoparticulate powder. Particle size and polydispersity index 
(PDI) were evaluated by photon correlation spectroscopy (PCS) using a Zetasizer Nano 
(Malvern Instruments, UK). Surface charge was measured using the same Zetasizer Nano 
equipment combined with laser Doppler velocimetry. ET loading determination was carried 
out after ET extraction from LN by a previously validated ultra-high-performance liquid 
chromatography tandem mass spectrometry (UHPLC-MS/MS) method 30. 
1.3.Cell culture 
Human cell lines HL-60 and K-562 (American Type Culture Collection, Manassas, VA, 
USA) were cultured at 5 x 105 cells/ml in RPMI supplemented with 20% (v/v) FBS, 100 
units/mL penicillin and 100 µg/mL streptomycin at 37ºC in a humidified incubator 
supplemented with 5% carbon dioxide. Cells were split 1:3-1:5 every 3-4 days.  
1.4.Study of endocytic pathways in leukemia cells: Quantification of internalized ET by 
UPLC-MS/MS 
HL-60 and K-562 cells were incubated with the different treatments: i) free ET; ii) ET-LN 
at a dose equivalent to 5 µg/ml (9.55 µM) of the free drug. For the study of the involvement 
of energy in the endocytosis, cells were incubated for 3 h at 37ºC or at 4ºC. For the 
inhibition of the internalization pathways, cells were pre-incubated with medium (control), 
Genistein (200 µM, 120 minutes), Methyl-β-cyclodextrin (5 mM, 60 minutes) and 
Chlorpromazine (30 µM, 60 minutes). Afterwards, cells were washed three times with PBS, 
treatments were added and cells were incubated for 5 h. Next, cells were harvested, washed 
three times with PBS and lysed. The total amount of proteins per sample was quantified 
using the Bradford assay and internalized ET was quantified by UPLC-MS/MS 30. 
1.5.Study of cell death mechanisms 
In brief, 4106 cells were grown in the presence of ET, non-loaded LN (Blank-LN) and ET-
LN in 25 cm2 culture flasks at 37ºC. According to the IC50 of both cell lines determined in 
our previous studies 10, 5 and 10 µg/mL (9.55 and 19.1 µM) of ET or equivalent 
concentrations of Blank-LN and ET-LN were selected for HL-60 and K-562 respectively. 
Afterwards, cells were collected to perform Western blot analysis.  
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Cells treated only with culture medium served as negative control for the experiment and 
cultures grown with EBSS starving medium and normal culture medium containing 1 µM 
of staurosporine served as positive controls for autophagy and apoptosis experiments 
respectively.  
1.6.Western Blot Analysis 
Cells were collected by centrifugation at 1500 rpm for 5 min, and were washed in PBS 
followed by detergent lysis (1% TRITON X-100, 1mM DTT), containing protease inhibitor 
cocktail. Protein concentration was determined by BRADFORD protein assay (Bio-Rad, 
Madrid, Spain).  
Equal protein amounts of each sample were resolved in 15% SDS polyacylamide gel for 
LC3 I/II detection, and 12% SDS polyacrylamide gel for the detection of the rest of 
proteins studied. Afterwards proteins were transferred to polyvinylidene difluoride 
membranes, washed with Tris buffered saline containing Tween (TBST) and blocked 1 h at 
RT with TBST containing 5% nonfat dry milk (TBSTM). Eventually, proteins of interest 
were detected by incubating overnight at 4ºC overnight in TBSTM with the following 
primary antibody dilutions: anti-PARP1 (1:2000), anti-caspase-3 (1:2000), anti-caspase-7 
(1:5000), caspase-9 (1:5000), and LC3 I/II (1:5000); as loading control, membranes were 
then incubated with anti-β-actin antibody (1:10000). Afterward, membranes were incubated 
with the corresponding anti-mouse or anti-rabbit secondary antibody (Sigma Aldrich, 
Madrid, Spain) in a 1:5000 dilution for 1 h at room temperature. Proteins were visualized 
by using enhanced chemiluminescence detection reagents (Amersham Biosciences, 
Barcelona, Spain). Band intensities were detected and quantified using a GE Healthcare 
ImageQuant ECL system with IQuant Capture ECL software (GE Healthcare, Madrid, 
Spain). Experiments were performed in triplicate. 
For apoptosis detection, cells were collected at 24, 48 and 72 h after adding treatments and 
for autophagy detection, immunoblot of LC3 I/II was performed in samples of 24 and 48 h. 
LC3 I refers to the unconjugated form of LC3 protein and LC3 II is the form of the protein 
which is present in autophagosomal membranes. Both forms differ in molecular weight (14 
and 12 KDa for LC3 I and LC3 II respectively), which allows its detection by western blot. 
Besides, LC3 II is rapidly degraded by lysosomal activity in autophagosomes. Thus 
lysosome degradation was blocked by adding 40mM of the lysosomotropic chemical 
NH4Cl, a V-ATPase-independent neutralyzer of lysosomal pH to the culture medium 4 h 
before collecting cells 31, 32.  
LC3 protein conversion was used as a marker of autophagy induction 33. Autophagy was 
measured by LC3 immunoblotting and quantification of LC3 II/LC3 I ratio as previously 
described 34.  
1.7.Statistical analysis 
Data are presented as a mean of three or more independent experiments, with error bars 
indicating the standard deviation. Statistical comparisons were performed by analysis of 
variance, and further post-hoc testing was conducted using the statistical software 
GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). Groups that are 
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significantly different from control are indicated in the figures as *p < 0.05, **p < 0.01; 
***p < 0.001. 
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RESULTS AND DISCUSSION 
1.1.Lipid Nanoparticle characterization 
The hot homogenization method consisting of high shear homogenization and 
ultrasonication provided LN with a size of 127.89 ± 9.95 nm and negative surface charge (-
28.42 ± 1.39). ET-LN loading was 22.677 ± 2.262 µg ET/mg of formulation. For in vitro 
experiments, ET-LN were resuspended at a maximum concentration of 440 µg/ml in cell 
culture media (the maximum quantity of ET-LN that can be resuspended in aqueous media 
is 12 mg/ml). LN size was evaluated in order to ensure that ET-LN were not aggregated.  
1.2.Uptake of ET and ET-LN, an energy-dependent mechanism? 
Phospholipids can be internalized in cells by a passive transport consisting of a spontaneous 
or a facilitated (mediated by flippase) trans-bilayer movement from the outer to the inner 
leaflet of the cell membrane, by an active transport mediated either by a translocator protein 
(ATP-dependent flippase), or via an endocytic mechanism 16. These mechanisms seem to 
be present in cell lines to a greater or lesser depending on the cell type. To assess the 
importance of endocytosis in ET and ET-LN uptake, leukemic cells were incubated with 
both treatments at 4ºC and at 37ºC. Results showed that ET and ET-LN uptake was energy-
dependent and, therefore, it was inhibited at 4ºC (Fig. 1).  
 
 
Figure 11. Graphic representation of edelfosine (ET) and lipid nanoparticles containing ET (ET-LN) 
internalization in HL-60 and K-562 cells after 3 h of incubation at different temperatures (4ºC and 
37ºC). Values are means of triplicates ± SD. *P < 0.05; **P < 0.01; ***P < 0.001. One-way ANOVA 
(Bonferroni post-test). 
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Relative to ET uptake, Fig. 1 shows that ET was internalized in a larger quantity (1.9 times 
higher) in HL-60 leukemia cells than in K-562 cells in normal culture conditions (37ºC). 
ET uptake was decreased when cells were incubated at 4ºC in both cell lines, confirming 
that an energy-dependent mechanism was involved in this uptake. Conversely, low 
temperature did not entirely prevent ET internalization, suggesting the implication of an 
energy-independent mechanism (passive transport) that seemed to be independent of the 
cell line as there were no significant differences in ET uptake in both cells lines at 4ºC. 
These results demonstrated that there might be a similar passive entry of ET in both cell 
lines and that, therefore, the differences in ET internalization in HL-60 and K-562 cells 
were due to the entry of the drug into the cells by an energy-dependent mechanism that 
predominates in HL-60 leukemia cells.  
Similarly, LN internalization also seemed to involve passive and active transport 
(endocytosis) 13. A higher internalization of drug (statistically significant in case of HL-60 
cells) was detected when cells were incubated at 37ºC. Besides, ET-LN were also 
incorporated in a similar rate by both cell lines at 4ºC. Previous studies have described the 
internalization of nanoparticles from 4 to 600 nm by passive membrane penetration in red 
blood cells 14, 35. Although large nanoparticles may produce local membrane deformation 
with subsequent hemolysis, Zhao et al. 35 showed that nanoparticles of 100 nm do not 
disturb erythrocytes’ cell membrane. Considering that the diameter of ET-LN was around 
100 nm, this uptake mechanism might be involved in ET-LN uptake. To our knowledge, 
there are no studies referring to LN passive transport in cells and this should therefore be 
studied further. The results obtained also indicated that encapsulating the drug in LN did 
not enhance its internalization in comparison to the free drug in either leukemia cell line. 
Encapsulated ET was internalized to a lesser extent by HL-60 cells than free drug, whereas 
it did not show any differences with respect to the free drug in K-562 cells. Besides, ET-LN 
were incorporated at similar rates by both cell lines.  
1.3.Effect of endocytosis inhibitors in ET and ET-LN uptake 
ET uptake mechanisms seem to be dependent on the cell line. Lipid raft internalization is 
common in leukemic cells whereas spontaneous flipping (to a lesser extent) or an energy-
dependent mechanism which involves a lipid transporter/translocase (flippase) is found in 
other cancer cells 16. In this sense, recent studies carried out by Rui Chen et al. 19 reported 
the involvement of the transmembrane protein subunit CD50a (TMEM30a) in the 
endocytosis of ET in mammalian cells. They demonstrated that ET endocytosis is an 
energy-dependent process mediated by TMEM30a in complex with a transmembrane 
phospholipid flippase (P4-ATPase). 
To get more insights into the mechanisms involved in ET and ET-LN uptake, cells were 
pre-incubated with different endocytosis inhibitors: chlorpromazine, methyl beta 
cyclodextrin (MβCD) and genistein. Afterwards, cells were grown in medium containing 
either the free or nanoencapsulated drug (5 µg/ml; 9.55 µM) and internalized drug was 
quantified and normalized with respect to the total amount of protein.  
Fig. 2 shows the results of the internalization of ET and ET-LN after pre-incubation of the 
cells with the inhibitors. Concerning the ET uptake, the internalization of the free drug in 
HL-60 cells was reduced by pre-incubating the cells with MβCD and Chlorpromazine 
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suggesting the implication of lipid rafts and clathrin-mediated endocytosis respectively. 
These results were in agreement with previous studies that refer to an accumulation of ET 
in lipid rafts in lymphoma and multiple myeloma cells and subsequent endocytosis 36-38.  
 
Figure 22. Uptake of edelfosine (ET) and lipid nanoparticles containing edelfosine (ET-LN) in HL-60 
and K-562 cells after pre-incubation of the cells with different endocytosis inhibitors for 5 h. Values are 
means of triplicates ± SEM. ***P < 0.001. One-way ANOVA (Bonferroni post-test). 
 
Clathrin-mediated endocytosis of ET has also been described in lymphoma and epidermal 
carcinoma cells 18. Although other authors have reported a passive uptake mechanism (not 
affected by endocytosis inhibitors) of ET in HL-60 cells 39, the present study showed a 
minor involvement of this ATP-independent entry of ET in HL-60 cells (Fig. 1). This 
energy-independent uptake might be mediated by ATP-independent flippases that non-
specifically flip-flop phospholipids across the plasmatic membrane 20, 40. 
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Regarding ET-resistant cell line K-562, the inhibition of endocytosis mechanisms induced a 
slight but non-significant decrease in ET internalization suggesting a minor role of CME 
and lipid rafts endocytosis in this cell line. Therefore, ET uptake mechanisms such as 
spontaneous flipping from the outer to the inner leaflet 16 might be responsible for the free 
drug uptake in K-562 resistant cells. 
Blocking CvME with genistein did not induce significant differences in free or 
encapsulated ET internalization in any of the two cell lines. Moreover, endocytosis 
inhibitors had no apparent effect in the internalization of ET-LN. Even though endocytosis 
of LN by caveolin 41 and clathrin 42 has been reported by other authors, we did not detect 
LN internalization via these routes in the present study. This might be due to a lack of 
caveolae protein in the plasmatic membrane of these cells, since, as stated by some authors, 
the expression and/or distribution of this protein might be dependent on the activation 
and/or maturation state of immune cells 43. Caveolae-mediated pathway should, therefore, 
not be discarded in other cancer cells. 
On the other hand, Guilleron et al 34 have recently showed that LN can be internalized via 
CME followed by macropinocytosis, suggesting that macropinocytosis could be the major 
endocytic process involved in LN uptake, after being activated after LN uptake by CME. 
Although we did not observe a CME of LN in this study, Guilleron et al. stated that the 
implication of CME in LN endocytosis accounted for less than 1% of total endocytic 
nanoparticles. Therefore, CME might also be occurring in our experiments although it was 
not possible to detect it. Macropinocytosis might be, therefore, the major endocytosis 
mechanism involved in ET-LN internalization. Nevertheless, phagocytosis might be also a 
reliable endocytic mechanism in these cells; indeed, HL-60 and K-562 are reported to 
express Fc receptors (FcR) 44, a heterogeneous group of cell membrane receptors involved 
in phagocytosis due to its binding to immunoglobulins (Ig). In addition, LN can be 
opsonized by several opsonic factors such as IgG 45 and, therefore, ET-LN might be being 
phagocytized by HL-60 cells. This phagocytic activity might be more relevant in case of 
HL-60 cells due to their neutrophilic origin 46. Nevertheless, it might be also feasible in K-
562 cells; indeed, this cell line is characterized by its multipotential profile and its capacity 
to spontaneously differentiate into recognizable progenitors of the erythrocytic, 
granulocytic and monocytic series 47.  
1.4.K-562 from HL-60 exhibit different molecular mechanisms that contribute to cell 
death in response to ET and ET-LN treatments 
As has been previously described by flow cytometry studies, both K-562 and HL-60 cell 
lines presented massive cell demise when grown in presence of ET-LN, and therefore the 
viability of cells was significantly reduced. In the case of the ET-sensitive HL-60 cell line, 
comparable levels of cell death were induced with the nanoencapsulated and the free drug. 
However, the IC50 of K-562 cell line was considerably reduced with the treatment with 
encapsulated drug, which inhibited its proliferation from the first 24 h of incubation at a 
ET-LN dose equivalent to 10 µg/ml of free drug 10. This reversion of resistance to ET in K-
562 could be attributed to an increased intracellular ET concentration after nanoparticle 
uptake or to an enhanced cell death mechanism due to the different intracellular localization 
of the drug. Higher intracellular accumulation of the drug with the ET-LN was discarded on 
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
Con formato: Color de fuente:
Automático
14 
 
the basis of the above results and, thus, different sensitivity to the treatments might depend 
on the death mechanisms triggered by both treatments.  
To gain further insights into mechanisms for apoptosis induction, caspase activation was 
studied at protein level in both cell lines. Thus, cells were grown in medium containing ET 
or ET-LN (5 and 10 µg/mL of ET or equivalent concentrations of Blank-LN and ET-LN for 
HL-60 and K-562 respectively) at several time points and proteins were subsequently 
obtained from cell lysates. Western blots were performed to detect effector caspase 
activation, which would entail apoptosis induction. Additionally, one of the first identified 
substrates of caspases, PARP1 was inspected. The processing of both effector caspases -7 
and -3 and their substrate, PARP1 was detected in ET- and ET-LN-treated HL-60 cells 
(Fig. 3), thereby indicating the same apoptotic cell induction of both treatment groups. 
These results might be explained due to the fact that HL-60 is ET-sensitive. Besides, the 
encapsulated drug might be rapidly internalized in HL-60 and released into the cell. Due to 
its sensitivity, low concentrations of ET might be enough to induce apoptosis. The 
abovementioned uptake studies indicate that ET may be internalized by other mechanisms 
apart from lipid rafts and that those mechanisms may be different from those involved in 
the uptake of ET-LN.  
 
Figure 33. Characterization of caspase activation status of HL-60 and K-562 after incubation with 
medium, free edelfosine (ET) and drug-loaded LN (ET-LN) at a dose equivalent to 5 and 10 µg/mL of 
ET respectively. Caspase activation was inspected by western blot. Protein extracts of cells grown in 
starvation EBSS medium (Starv 3h), Staurosporine (STS), untreated control cells (C) and unloaded 
nanoparticles (Blank-LN) were included as controls. 
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On the other hand, K-562 did not display caspase-mediated apoptosis when treated with 
either ET or drug-loaded LN, as processed forms of inductor caspase-9 and effector 
caspases-3 and -7 were not detected in protein extracts (Fig. 3). 
The K-562 cell line was derived from a chronic myelogenous leukemia (CML) blast crisis 
patient 48 and therefore it presents several characteristics of this stage of the disease, such as 
hyperproliferation and apoptosis resistance. For that reason, the resistance of K-562 to 
apoptosis induction has been extensively reported 49-52. This resistance may be attributed to 
Bcr-Abl expression. Besides, low ganglioside levels in cell membrane and ERK/MAPK 
overactivation among others may have an important role in the resistance of this cell line 53, 
54. These molecular particularities would explain the absence of caspase-mediated cell 
death in K-562 in response to the treatments. 
The abovementioned results indicate that HL-60 cell line induced caspase-mediated cell 
death in response to free and ET-LN treatments whereas K-562 exhibited an enhanced 
resistance in inducing the processing and activation of pro-caspases and therefore in 
inducing apoptosis via caspase activation. These findings confirm our previous 
observations using flow cytometry that showed absence of caspase activation in K-562 
cells after treatment with either ET or ET-LN 10. Therefore, mechanisms different from 
caspase activation may have a role in cell induction in K-562 cell line. 
1.5.Increase of autophagy-associated LC3 II protein in response to ET and ET-LN 
treatments. 
We have previously hypothesized that this different induction of cell death by ET-LN 
might be related to a distinct entry route of the drug into the cell when it is encapsulated 10, 
causing a different intracellular location of ET. In the above uptake studies we showed that 
ET endocytosis in K-562 cells was low, suggesting the major implication of passive flip-
flop of ET in these cells. This uptake would promote direct delivery of the drug in the 
cytoplasm whereas the encapsulated ET intracellular traffic might be mediated by 
macropinosomes and phagosomes. Then, vesicles might: i) directly fuse with lysosomes or 
be engulfed by into double-membrane vesicles called autophagosomes which will later fuse 
with lysosomes. In addition, the aforementioned absence of caspase activation would 
indicate that K-562 cells might undergo a caspase-independent cell death mechanism. 
Hence, autophagic cell death could have a role in the cell demise induced by ET-LN in K-
562 cells. To gain a better insight, LC3 I and LC3 II protein levels were inspected via 
western blot and subsequent band quantification. LC3 is a ubiquitin-like protein that can be 
detected unconjugated (LC3 I) or associated with autophagosomal membranes (LC3 II). 
Thus, LC3 II levels are augmented during autophagy. Accordingly, an increase in the ratio 
of LC3 II to LC3 I reflects the accumulation of autophagic vesicles in cells, and therefore 
autophagy induction.  
For that reason, the status of autophagy was inspected in order to detect an increase in LC3 
II/LC3 I ratio (Fig. 4). In both cell lines, the ratio increased in all the groups after 24 h of 
treatment. This could be explained as a response to cell stress produced due to the change 
of the culture conditions (that is, the presence of the nanoparticles or the free drug in the 
cellular media) 55. At 48 h after treatment, Blank-LN control group recovered similar 
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expression levels to the untreated control whereas those of the treated cells rose. This 
increase reached statistical significance at 48 h in K-562 cells, indicating an increase of 
LC3 II compared to LC3 I in nanoparticle-treated cells, which in turn entails a higher 
presence of autophagosomes in treated cells 10.  
 
Figure 44. LC3 protein expression in HL-60 and K-562 cells after 24 and 48 h of treatment with 
edelfosine (ET) and lipid nanoparticles containing edelfosine (ET-LN) at a dose equivalent to 5 and 10 
µg/mL of ET respectively. LC3I and LC3II were detected by western blot. Protein extracts of cells 
grown in starvation EBSS medium (Starv 3h), Staurosporine (STS), untreated control cells (C) and 
unloaded nanoparticles (Blank-LN) were included as controls. Graphs depict the fold increase of LC3 
II/LC3 I ratio relative to untreated control cells. Values are means of triplicates ± SEM. **P<0.01 vs. 
Blank-LN control by one-way ANOVA (Bonferroni post-test). 
 
Hence, both K-562 ET and ET-LN-treated cells presented high levels of LC3 II/LC3 I at 48 
h, although cultures treated with encapsulated drug underwent a strong cell death induction 
not detected with the free drug.  
The observed autophagosome induction may be due to a deleterious overactivation of 
defense mechanism caused by the treatment or might indicate that autophagic cell death 
could be responsible for the cytotoxicity of the LN. Autophagy activation may stand for a 
cellular attempt to cope with stress induced by cytotoxic agents as several anticancer 
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therapies induce the accumulation of autophagosomes in tumor cell lines in vitro 56, 57.  
Mishima and colleagues have described the excessive autophagy in K-562, associated with 
treatment of 12-O-tetradecanoyl-phorbol-13-acetate (TPA); and after notable autophagic 
degradation, the cells finally underwent autophagic cell death, suggesting that autophagy 
regulated two mechanisms in K-562 cells: both the cell survival system and autophagic cell 
death 58. In that sense, the observed autophagy induction in K-562 cell line might be a 
reflection of an stress situation that the cell undergoes in presence of either the 
nanoencapsulated and the free drug. In addition, ET could be internalized in K-562 by a 
passive flip-flop mechanism although a minor implication of CME and lipid raft 
endocytosis could be also involved while phagocytosis and macropinocytosis might be the 
preferential mechanisms implied in ET-LN uptake in these cells. Therefore, ET might be 
mainly delivered to the cytoplasm whereas ET-LN might suffer macroendocytic vacuole 
trafficking. These differences in uptake in both treatments could entail different subcellular 
locations of ET in K-562 cells, and therefore different effects on subcellular machinery. In 
addition, LN could be recycled into the cell, as previously reported 59. ET hydrolysis by 
lysosome fusion in autolysosomes may be counteracted in ET-LN due to its encapsulation, 
and therefore ET might be protected from lysosomal degradation. Afterwards, permeases 
would facilitate the release of the resulting products into the cytoplasm and organelles, 
were ET-LN would exert its toxic effects in intracellular membranes (i.e disruption of 
autophagosome, ER or Golgi membranes), inducing cell death or inducing permeability 
transition and/or rupture of the lysosomal membrane 60, provoking the release of lysosomal 
enzymes to the cytoplasm due to an increase in the lysosomal membrane permeability, that 
has been reported to trigger apoptotic cell death. Thus, the aforementioned equilibrium 
between cell life and stress-induced demise could have been broken towards cell death in 
ET-LN treated cells due to the different toxic mechanisms exerted by ET when it is 
incorporated in the nanoparticles. In such situations, the cells could not cope with the stress 
and would be driven to cell death.  
On the other hand, ET-LN would alter the autophagic machinery in cells. Ma et al. 61 
reported that gold nanoparticles induced an accumulation of autophagic vacuoles through 
lysosomal impairment. The authors described that autophagosome accumulation was 
induced by a blockage of the autophagic flux rather than induction of autophagy. Such 
interference with lysosomal function might also eventually lead to cell death and would 
also explain the results observed with K-562.  
In addition, many efforts are being made to further understand the crosstalk between 
necrosis, autophagy and apoptosis 62, 63. For this reason, the novel autophagic induction 
described in the present paper in response to ET-LN treatment could induce a caspase-
independent cell death mechanism (i.e caspase independent apoptosis or necrosis). To our 
knowledge this study represents the first report on the possible role of autophagy in the 
cellular response to LN.  
CONCLUSION 
The data presented above provide evidence that ET and ET-LN intracellular incorporation 
is prompted by different uptake mechanisms. Endocytic (HL-60) and facilitated diffusion 
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(HL-60 and K-562) appear to be major uptake mechanisms in free drug uptake, whereas, in 
case of ET-LN, passive diffusion, phagocytosis and macropinocytosis are the most likely 
uptake mechanisms. LN do not enhance the intracellular concentration of the drug in both 
leukemic cell lines despite the different uptake mechanism of ET-LN. Besides, both 
treatments activate caspase-mediated cell death in the ET-sensitive cell line HL-60, while 
conversely in K-562 caspases were not activated. Moreover, an important increase in 
lipidated LC3 II was detected after both treatments, pointing towards an increase of 
autophagic vesicles in K-562 cells. Importantly, as ET-LN overcome the resistance of K-
562 cells, autophagic cell death could be involved in the cell demise process caused by the 
toxic effects of ET when it is incorporated in the nanoparticles at a subcellular location 
different from the free drug.  
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